Is there a Vietnamese version of Pemigatinib?

Pemigatinib (Pemigatinib) has not yet been officially released in the Vietnamese market. Pemetinib is a targeted drug developed and produced by Incyte Corporation in the United States. It is mainly used to treat cholangiocarcinoma (CCA) and other tumors related to FGFR gene rearrangements. Although pemetinib has been approved by drug regulatory agencies and marketed in the United States, the European Union and other regions, there is no formal sales channel in the Vietnamese market.

Since pemetinib is a new type of targeted drug and its indications and treatment areas are still expanding globally, the marketing approval in Asian markets such as Vietnam may be affected by some policies and regulations. The regulatory procedures of the Vietnamese pharmaceutical market are different from those of other international markets, which may result in the introduction of pemetinib being slower. If patients need to use the drug, they may need to obtain it through legal import channels. However, this may also face problems such as high cost and legality of the drug. Therefore, there is currently no convenient way to obtain pemetinib for Vietnamese patients.

As the global cancer targeted therapy market continues to develop, generic pemetinib may gradually enter the market in Southeast Asian countries such as Vietnam in the future. The demand for cancer treatment in Southeast Asia is growing, especially in the treatment of malignant tumors such as cholangiocarcinoma, and the market demand for such targeted drugs is increasing. In the future, with the further liberalization of Vietnam's drug approval process, pemetinib's original drug or its generic drugs may enter the local market, providing patients with more treatment options.

Nonetheless, patients should still be cautious when choosing pemetinib to ensure that the drug they purchase complies with local drug regulatory standards and avoid the risk of counterfeit or inferior drugs.

Reference materials:https://go.drugbank.com/drugs/DB15102